Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company to Present Interim Analysis Secondary Endpoint Data Including Progression-free Survival from Phase III TIGeR-PaC Study, a Multi-center Open-label Study Evaluating RenovoGem™ to Treat... | May 25, 2023
83% of glioblastoma patients remain alive after 14 months on study, a percentage well above what is expected for the enrolled population of chemotherapy refractory patients Survival data will
Rain Oncology Inc. announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in patients with dedifferentiated liposarcoma , did... | May 23, 2023
New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel will be presented at the 2023 American Society of Clinical Oncology ... | May 18, 2023
By Chris Wack Ultragenyx Pharmaceutical said Wednesday that the U.S. Food and Drug Administration has reviewed and agreed to a protocol amendment to a Phase 1/2 study evaluating the safety and... | May 17, 2023